Welcome to our dedicated page for Elicio Therapeutics news (Ticker: ELTX), a resource for investors and traders seeking the latest updates and insights on Elicio Therapeutics stock.
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a clinical-stage biotechnology company developing a pipeline of investigational cancer immunotherapies built on its Amphiphile (AMP) platform. This news page aggregates company press releases and market-moving updates related to Elicio’s clinical programs, platform research, and corporate developments.
Recent news from Elicio has focused on its lead program ELI-002, an AMP-based, off-the-shelf immunotherapy targeting cancers driven by KRAS mutations. The company regularly reports immunogenicity data from the Phase 2 AMPLIFY-7P trial in mKRAS pancreatic ductal adenocarcinoma, including mKRAS-specific T cell response rates, CD4 and CD8 activation, antigen spreading to non-mKRAS neoantigens, and analyses across diverse HLA backgrounds. These updates provide insight into how ELI-002 7P may elicit broad, mutation-directed immune responses in high-risk patients.
In addition to clinical readouts, Elicio’s news flow includes announcements about preclinical findings for intratumoral ELI-004, presentations at scientific meetings such as the Society for Immunotherapy of Cancer and ESMO Immuno-Oncology Congress, and investigator-initiated trials combining ELI-002 7P with chemotherapy and checkpoint inhibitors in pancreatic cancer. Corporate updates, including financial results, cash runway commentary, and executive appointments, also feature prominently in the company’s disclosures.
Investors and observers following ELTX news can use this page to review Elicio’s latest statements on its AMP platform, off-the-shelf immunotherapy strategy, and development plans in mKRAS-positive pancreatic and colorectal cancers, as well as emerging programs targeting BRAF and p53 mutations. Bookmark this feed to monitor new trial data, regulatory-related communications, and other material events reported by the company.
Elicio Therapeutics (NASDAQ:ELTX) has announced a significant advancement in pancreatic cancer treatment with a new Phase 1 investigator-initiated trial for their immunotherapy drug ELI-002 7P. The study, led by Memorial Sloan Kettering Cancer Center and funded by the Lustgarten Foundation, will evaluate ELI-002 7P in combination with chemotherapy (mFOLFIRINOX) and an anti-PD1 checkpoint inhibitor.
The trial will focus on borderline and resectable pancreatic ductal adenocarcinoma (PDAC) patients, enrolling 20 patients across two cohorts (10 per arm). The study aims to convert immunologically "cold" tumors to T-cell-inflamed "hot" tumors, potentially improving surgical outcomes and long-term survival. The trial is expected to begin in H1'2026.
Elicio Therapeutics (Nasdaq: ELTX) has granted 9,800 inducement stock options to two new employees on September 15, 2025. The options were priced at $10.08 per share with a four-year vesting schedule, starting with 25% vesting after the first year.
The company, specializing in novel immunotherapies for cancer treatment, highlighted its lead program ELI-002, an off-the-shelf vaccine targeting KRAS mutations. Recent Phase 1 AMPLIFY-201 data showed promising results with 16.3-month median recurrence-free survival and 28.9-month median overall survival in pancreatic and colorectal cancer patients.
Elicio Therapeutics (NASDAQ:ELTX) reported impressive immunogenicity data from its ongoing Phase 2 AMPLIFY-7P trial for ELI-002 7P, its investigational vaccine immunotherapy. The trial demonstrated that 99% of evaluable patients (89 of 90) generated strong mKRAS-specific T cell responses, with an average increase of 145.3x over baseline.
Key highlights include 85% of patients showing both mKRAS-specific CD4 and CD8 T cells, and 87.6% of patients demonstrating response to their specific tumor antigen. The results are consistent with previous Phase 1 trials, where T cell responses correlated with clinical activity in minimal residual disease positive (MRD+) patients. The final disease-free survival analysis is expected in Q4 2025.
Elicio Therapeutics (NASDAQ:ELTX) announced updated Phase 1 AMPLIFY-201 follow-up data for ELI-002 published in Nature Medicine. At 19.7 months median follow-up, the study showed significant improvements in survival metrics for minimal residual disease-positive, adjuvant-stage patients.
Key findings include median overall survival increasing to 28.94 months from 16.33 months, with patients showing T cell responses above threshold experiencing a 77% reduction in death risk and 88% reduction in relapse risk. The treatment demonstrated strong efficacy with 84% of patients showing mKRAS-specific T cell responses and tumor biomarker responses.
The final disease-free survival analysis for the Phase 2 AMPLIFY-7P study in pancreatic ductal adenocarcinoma is expected in Q4 2025. The therapy was well-tolerated with no safety concerns or dose-limiting toxicities reported.
Elicio Therapeutics (NASDAQ:ELTX) reported Q2 2025 financial results and provided updates on its cancer immunotherapy pipeline. The Independent Data Monitoring Committee (IDMC) recommended continuing the ELI-002 7P Phase 2 study in pancreatic cancer without modifications, with final disease-free survival (DFS) analysis expected in Q4 2025.
Financial highlights include a $10 million non-dilutive financing secured in June 2025. Q2 2025 showed R&D expenses of $7.0 million (down from $8.2M in Q2 2024) and a net loss of $10.6 million. Cash position of $22.1 million is expected to fund operations into Q1 2026, beyond the anticipated Phase 2 final analysis.
The company plans to request an End-of-Phase 2 FDA meeting to finalize the regulatory strategy for ELI-002's pivotal Phase 3 trial following the final DFS analysis.
Elicio Therapeutics (NASDAQ:ELTX) announced that the Independent Data Monitoring Committee (IDMC) has recommended continuing the Phase 2 AMPLIFY-7P study of ELI-002 7P for pancreatic cancer without modifications. The trial, involving 144 patients across 24 U.S. sites, evaluates ELI-002 7P's effectiveness against standard of care in improving disease-free survival (DFS) for pancreatic ductal adenocarcinoma (PDAC) patients.
The IDMC's positive recommendation suggests preliminary efficacy signals and confirms a favorable safety profile. The final DFS analysis is expected in Q4 2025. Notably, Elicio has already aligned with the FDA on key elements of the planned Phase 3 study design and maintains a cash runway extending into Q1 2026.
Elicio Therapeutics (NASDAQ: ELTX) reported its Q1 2025 financial results and provided corporate updates. The company is advancing toward a crucial Phase 2 AMPLIFY-7P interim analysis expected in Q3 2025, focusing on disease-free survival in pancreatic cancer treatment. Key financial highlights include: R&D expenses of $7.8M (up from $7.6M in Q1 2024), G&A expenses of $3.0M (up from $2.7M), and a net loss of $11.2M ($0.87 per share). The company's cash position of $18.4M is expected to support operations into Q4 2025.
Notable developments include FDA alignment on key Phase 3 study design elements for ELI-002, appointment of Preetam Shah as Chief Strategy and Financial Officer, and a $10M registered direct offering. ELI-002 represents a potential breakthrough in treating mKRAS-driven tumors, particularly for pancreatic cancer patients with a 13% 5-year survival rate.
Elicio Therapeutics (Nasdaq: ELTX) has announced inducement awards for its newly appointed Chief Strategy and Financial Officer, Preetam Shah, and two other new employees. The grants were approved under the Elicio 2024 Inducement Incentive Award Plan in accordance with Nasdaq Listing Rule 5635(c)(4).
Dr. Shah received 191,624 stock options, while the two additional employees were granted a total of 21,000 stock options. All options are priced at $4.98 per share, matching Elicio's closing price on April 15, 2025. The options vest over four years, with 25% vesting on the first employment anniversary and the remainder vesting monthly thereafter, contingent on continued employment.